Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
08/03/2021 14:18
March 8 (Reuters) - Axim Biotechnologies Inc AXIM.PK :
* AXIM® BIOTECHNOLOGIES SUCCESSFULLY COMPLETES POINT-OF-CARE
CLINICAL TRIALS ON ITS RAPID COVID-19 NEUTRALIZING ANTIBODY TEST
Source text for Eikon: ID:nGNX1v5lqj
Further company coverage: AXIM.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2